Literature DB >> 743845

Primary Thompson prosthesis for acute femoral neck fractures.

S P Montgomery, L R Lawson.   

Abstract

Two hundred fifty cases of F.R. Thompson endoprosthesis replacement without methylmethacrylate in acute femoral neck fractures between 1969 and 1973 were reviewed. Follow-up evaluation was obtained in 94 patients averaging 4.8 years postoperative utilizing the Harris hip questionnaire. None of the patients were personally examined, but each was interviewed and rated for pain, function, and satisfaction with the hip surgery. The average Harris score was 63 points giving 56% overall satisfactory results. Pain relief was satisfactory in 85% of cases. Functional results were 71% fair or better, and 90% were satisfied with the overall results. Mortality at one year postoperative was 23%. Incidence of deep wound infection was 2% and prosthesis dislocation was 1%. Both infection rate and dislocation rate were higher in posterior exposure compared to anterior lateral surgical approach. The lack of methylmethacrylate cement apparently did not delay postoperative ambulation, as 60% of all patients were discharged within 4 weeks of fracture. The indications for methylmethacrylate with the Thompson endoprosthesis is an unanswered question and requires further investigation.

Entities:  

Mesh:

Year:  1978        PMID: 743845

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Treatment of femoral neck fractures in elderly patients over 60 years of age - which is the ideal modality of primary joint replacement?

Authors:  Christian Ossendorf; Max J Scheyerer; Guido A Wanner; Hans-Peter Simmen; Clément Ml Werner
Journal:  Patient Saf Surg       Date:  2010-10-20

2.  Changes in implant choice and surgical technique for hemiarthroplasty. 21,346 procedures from the Swedish Hip Arthroplasty Register 2005-2009.

Authors:  Olof Leonardsson; Göran Garellick; Johan Kärrholm; Kristina Akesson; Cecilia Rogmark
Journal:  Acta Orthop       Date:  2011-11-23       Impact factor: 3.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.